Latest News
Organon licenses MIUDELLA IUD from Sebela Pharmaceuticals
23 February 2026 - Healthcare company Organon (NYSE:OGN) said on Monday that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD).The transaction...
Formosa Pharmaceuticals signs licensing deal with Arrotex for APP13007 in Australia and New Zealand
...
Gilead to acquire Arcellx to gain full control of anito-cel
23 February 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Monday that it has agreed to acquire Arcellx (NASDAQ:ACLX) for USD115 per share in cash plus a USD5 contingent value right, implying an equity value of USD7.8...
Novo Nordisk's CagriSema achieves 23% weight loss but misses primary endpoint in REDEFINE 4 trial
23 February 2026 - Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) on Monday reported results from the open-label phase 3 REDEFINE 4 trial evaluating CagriSema, a combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, in 80...
NICE recommends epcoritamab for relapsed or refractory follicular lymphoma
...